The Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity in Type 2 Diabetes
Type 2 Diabetes
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
- Change in insulin sensitivity after RYGB [ Time Frame: 1 week, 3 months, 1 year ] [ Designated as safety issue: No ]
- Change in insulin secretion in response to oral glucose after RYGB [ Time Frame: 3 months, 1 year ] [ Designated as safety issue: No ]
- Change in insulin secretion after iv glucose-glucagon after RYGB [ Time Frame: 1 week, 3months, 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||September 2010|
|Study Completion Date:||March 2013|
|Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
RYGB patients with type 2 diabetes
Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
RYGB patients without type 2 diabetes
Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
Obesity has become a severe epidemic globally. With the rapid increase in obesity comes a pronounced rise in obesity-related disorders, especially type 2 diabetes. Weight loss achieved through lifestyle changes improves diabetes, but is very difficult to maintain over time. In contrast, Roux-en-Y gastric bypass (RYGB) surgery can induce long-term weight loss and remission of diabetes. Surprisingly, the resolution of type 2 diabetes occurs within days after surgery and before significant weight loss. The resolution of diabetes must therefore be explained by a response to the surgical alterations of the stomach and intestines: restriction in gastric volume and bypass of the stomach, duodenum and proximal jejunum.
Severe insulin resistance in muscle and liver is the common defect in obesity and type 2 diabetes and may be improved or even reversed shortly after the operation. The aim of this study is to examine the acute changes in insulin sensitivity of muscle and liver by using hyperinsulinaemic euglycaemic clamp combined with glucose tracer to assess hepatic glucose production. Insulin signaling pathways will be studied in biopsies from muscle and subcutaneous fat as to explain the molecular basis of the changes in insulin sensitivity after RYGB.
Insulin secretion will be evaluated in response to oral glucose as well as iv glucose-glucagon.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01202526
|Hvidovre University Hospital|
|Copenhagen, Hvidovre, Denmark, DK-2650|
|Principal Investigator:||Anna Kirstine Bojsen-Møller, MD||Hvidovre University Hospital|